Regeneron Pharmaceuticals has announced a plan to acquire the bankrupt genetic testing company 23andMe for $256 million, raising privacy concerns as the pharmaceutical giant will gain access to the genetic data of over 15 million customers. The New York Post reports that Regeneron Pharmaceuticals has seized the opportunity to acquire the once-thriving genetic testing company 23andMe, which recently filed for bankruptcy. The $256 million deal will grant Regeneron access to 23andMe’s extensive collection of genetic samples and data, encompassing the personal information of more than 15 million customers. This acquisition has raised significant concerns among privacy advocates and customers who...